Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) and delayed tumor growth. The results from this study were published in the Journal of the National Cancer Institute (https://doi.org/10.1093/jnci/djx121).

 

https://www.genkyotex.com/images/PDF/GB/03082017_PR_GKTX_JNCI_Publication.pdf